Frequent PVT1 rearrangement and novel chimeric genes PVT1-NBEA and PVT1-WWOX occur in multiple myeloma with 8q24 abnormality.

Chromosome 8q24 rearrangements are occasionally found in multiple myeloma and are associated with tumor progression. The 8q24 rearrangements were detected by FISH in 12 of 54 patients with multiple myeloma (22.2%) and in 8 of 11 multiple myeloma cell lines (72.7%). The breakpoints of 8q24 in 10 patients with multiple myeloma and in all multiple myeloma cell lines were assigned to a 360 kb segment, which was divided into 4 regions: approximately 120 kb centromeric to MYC (5' side of MYC), the region centromerically adjacent to PVT1 (~ 170 kb region, including MYC, of 5' side of PVT1), the PVT1 region, and the telomeric region to PVT1. PVT1 rearrangements were most common and found in 7 of 12 patients (58.3%) and 5 of 8 cell lines (62.5%) with 8q24 abnormalities. A combination of spectral karyotyping (SKY), FISH, and oligonucleotide array identified several partner loci of PVT1 rearrangements, such as 4p16, 4q13, 13q13, 14q32, and 16q23-24. Two novel chimeric genes were identified: PVT1-NBEA in the AMU-MM1 cell line harboring t(8;13)(q24;q13) and PVT1-WWOX in RPMI8226 cell line harboring der(16)t(16;22)ins(16;8)(q23;q24). The PVT1-NBEA chimera in which PVT1 exon 1 was fused to NBEA exon 2 and the PVT1-WWOX in which PVT1 exon 1 was fused to WWOX exon 9 were associated with the expression of abnormal NBEA and WWOX lacking their N-terminus, respectively. These findings suggest that PVT1 rearrangements may represent a novel molecular paradigm underlying the pathology of 8q24 rearrangement-positive multiple myeloma.

[1]  Y. Akao,et al.  Bcl-2 is a better therapeutic target than c-Myc, but attacking both could be a more effective treatment strategy for B-cell lymphoma with concurrent Bcl-2 and c-Myc overexpression. , 2011, Experimental hematology.

[2]  I. Hanamura,et al.  Establishment and Characterization of a Novel Human Myeloma Cell Line, AMU-MM1, From a Multiple Myeloma Patient Involving Central Nerve System After Treatment with Bortezomib , 2010 .

[3]  B. Barlogie,et al.  International Myeloma Working Group molecular classification of multiple myeloma: spotlight review , 2009, Leukemia.

[4]  N. Cross,et al.  Loss of 1p and rearrangement of MYC are associated with progression of smouldering myeloma to myeloma: sequential analysis of a single case , 2009, Haematologica.

[5]  J. Carpten,et al.  Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglobulinemia. , 2009, Cancer research.

[6]  R. Vij,et al.  Neurobeachin (NBEA) is a target of recurrent interstitial deletions at 13q13 in patients with MGUS and multiple myeloma. , 2009, Experimental hematology.

[7]  R. Siebert,et al.  Identification of candidate tumour suppressor gene loci for Hodgkin and Reed‐Sternberg cells by characterisation of homozygous deletions in classical Hodgkin lymphoma cell lines , 2008, British journal of haematology.

[8]  P. L. Bergsagel,et al.  Characterization of MYC translocations in multiple myeloma cell lines. , 2008, Journal of the National Cancer Institute. Monographs.

[9]  Y. Hayashi,et al.  Identification of the novel AML1 fusion partner gene, LAF4, a fusion partner of MLL, in childhood T-cell acute lymphoblastic leukemia with t(2;21)(q11;q22) by bubble PCR method for cDNA , 2008, Oncogene.

[10]  R. Stephens,et al.  The Identification of MicroRNAs in a Genomically Unstable Region of Human Chromosome 8q24 , 2008, Molecular Cancer Research.

[11]  K. Mimori,et al.  Clinical significance of the reduced expression of G protein gamma 7 (GNG7) in oesophageal cancer , 2008, British Journal of Cancer.

[12]  A. Al-Katib,et al.  Chromosome aberrations in a series of 120 multiple myeloma cases with abnormal karyotypes , 2007, American journal of hematology.

[13]  Letizia Carramusa,et al.  The PVT‐1 oncogene is a Myc protein target that is overexpressed in transformed cells , 2007, Journal of cellular physiology.

[14]  Wen-Lin Kuo,et al.  Amplification of PVT1 Contributes to the Pathophysiology of Ovarian and Breast Cancer , 2007, Clinical Cancer Research.

[15]  L. Bruhn,et al.  Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. , 2007, Cancer cell.

[16]  L. Staudt,et al.  Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. , 2007, Cancer cell.

[17]  David R Williams,et al.  Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. , 2006, Blood.

[18]  Yongsheng Huang,et al.  Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. , 2006, Blood.

[19]  R. Siebert,et al.  Identification of recurrent chromosomal breakpoints in multiple myeloma with complex karyotypes by combined G-banding, spectral karyotyping, and fluorescence in situ hybridization analyses. , 2006, Cancer genetics and cytogenetics.

[20]  Shigeru Chiba,et al.  A robust algorithm for copy number detection using high-density oligonucleotide single nucleotide polymorphism genotyping arrays. , 2005, Cancer research.

[21]  Y. Pekarsky,et al.  Functional association between Wwox tumor suppressor protein and p73, a p53 homolog. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[22]  H. Aburatani,et al.  An opposing view on WWOX protein function as a tumor suppressor. , 2003, Cancer research.

[23]  M. Rocchi,et al.  Heterogeneous pattern of chromosomal breakpoints involving the MYC locus in multiple myeloma , 2003, Genes, chromosomes & cancer.

[24]  R. Bataille,et al.  Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors. , 2001, Blood.

[25]  R. Bataille,et al.  Cytogenetic, interphase, and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia: a study of 40 patients at diagnosis, on behalf of the Intergroupe Francophone du Myélome and the Groupe Français de Cytogénétique Hématologique. , 2001, Blood.

[26]  B. Barlogie,et al.  Multicolour spectral karyotyping identifies new translocations and a recurring pathway for chromosome loss in multiple myeloma , 2001, British journal of haematology.

[27]  Friedrich W. Herberg,et al.  Neurobeachin: A Protein Kinase A-Anchoring,beige/Chediak-Higashi Protein Homolog Implicated in Neuronal Membrane Traffic , 2000, The Journal of Neuroscience.

[28]  A. Bednarek,et al.  WWOX, a novel WW domain-containing protein mapping to human chromosome 16q23.3-24.1, a region frequently affected in breast cancer. , 2000, Cancer research.

[29]  P. L. Bergsagel,et al.  Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[30]  N. Kakazu,et al.  Combined spectral karyotyping and DAPI banding analysis of chromosome abnormalities in myelodysplastic syndrome , 1999, Genes, chromosomes & cancer.

[31]  E. Macintyre,et al.  Simultaneous detection of MYC, BVR1, and PVT1 translocations in lymphoid malignancies by fluorescence in situ hybridization , 1998, Genes, chromosomes & cancer.

[32]  S. Kitano,et al.  Identification and Cloning of Human G-Protein γ 7, Down-regulated in Pancreatic Cancer , 1998 .

[33]  M. Taniwaki,et al.  The Ig heavy chain gene is frequently involved in chromosomal translocations in multiple myeloma and plasma cell leukemia as detected by in situ hybridization. , 1997, Blood.

[34]  M. Taniwaki,et al.  Translocations and amplification of the BCL2 gene are detected in interphase nuclei of non-Hodgkin's lymphoma by in situ hybridization with yeast artificial chromosome clones. , 1995, Blood.

[35]  B. Barlogie,et al.  Cytogenetic findings in 200 patients with multiple myeloma. , 1995, Cancer genetics and cytogenetics.

[36]  K. Huppi,et al.  Chimeric transcripts with an open reading frame are generated as a result of translocation to the Pvt‐1 region in mouse B‐cell tumors , 1994, International journal of cancer.

[37]  A. Palumbo,et al.  Human homologue of Moloney leukemia virus integration-4 locus (MLVI-4), located 20 kilobases 3' of the myc gene, is rearranged in multiple myelomas. , 1990, Cancer research.

[38]  R. Benner,et al.  Amplification of the c-myc and the pvt-like region in human multiple myeloma. , 1990, Oncogene.

[39]  I. Magrath,et al.  Localization of breakpoints by polymerase chain reactions in burkitt's lymphoma with 8;14 translocations , 1990 .

[40]  J. Bishop,et al.  Effects of translocations on transcription from PVT , 1990, Molecular and cellular biology.

[41]  J. Bishop,et al.  The PVT gene frequently amplifies with MYC in tumor cells , 1989, Molecular and cellular biology.

[42]  B. Barlogie,et al.  Plasma Cell Karyotype in Multiple Myeloma , 1988 .

[43]  E. Rassart,et al.  Proviral integration site Mis-1 in rat thymomas corresponds to the pvt-1 translocation breakpoint in murine plasmacytomas , 1986, Molecular and Cellular Biology.

[44]  P. Bevan,et al.  Analysis of G banded karyotypes in myeloma cells. , 1986, Journal of clinical pathology.

[45]  Wei Huang,et al.  Frequent epigenetic inactivation of the receptor tyrosine kinase EphA5 by promoter methylation in human breast cancer. , 2010, Human pathology.

[46]  M. Schwab,et al.  The neurobeachin gene spans the common fragile site FRA13A , 2005, Human Genetics.

[47]  G. Klein,et al.  Amplification of c-myc and pvt-1 homologous sequences in acute nonlymphatic leukemia. , 1988, Leukemia research.